About Us

Apobiologix: Focused on the Development and Distribution of Biosimilar Therapies
Image of scientists
Overview
Leadership

Invention Is Not the Only Innovation.

Traditional companies focus their innovative efforts on the discovery of new drugs that save and improve lives. Apobiologix sees a need to go further: to create sustainable health care that doesn't sacrifice quality or patient support. That's why biosimilars also require innovation.

Image of a chemist.

Apobiologix is focused on the development of biosimilars that combine the quality and value you need with the level of comprehensive support you expect.

Because at Apobiologix, we don't believe that innovation stops at invention.

Experienced in the Development and Marketing of Biosimilars

Apobiologix has experience in the successful development and marketing of biosimilar products. In October 2013, Grastofil (filgrastim) was launched in the EU for all approved uses of its innovator biologic.

Image of a chemist.

Key areas of focus include:

  • Global nonclinical and clinical program management
  • Global product development and regulatory experience
  • Manufacturing capabilities that ensure a constant level of product supply to our market
  • Dedicated Medical Affairs team
  • Dedicated commercial infrastructure
  • Market access and reimbursement support
  • Patient Assistance Program
Timeline of Apobiologix's initiation and product releases.

Invention is not the only innovation.

Apobiologix logo

2400 North Commerce Parkway,
Suite 300,
Weston, Florida 33326

855-276-7744

Email


Grastofil™ is a trademark of Apotex Technologies Inc. Neupogen® and Neulasta® are registered trademarks of Amgen.

  1. IMS Institute for Healthcare Informatics. Developments in cancer treatments, market dynamics, patient access, and value. May 2015.
  2. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy and costs. JAMA Oncol. 2015;1:539-540. p1, PP1.
  3. Jilma B, Jagiello-Gruszfeld A, Tomczal P, et al. Demonstration of clinical comparability of the biosimilar filgrastim to Neupogen, in terms of safety and efficacy, in healthy volunteers and patients receiving myelosuppressive chemotherapy. Eur Oncol Haematol. 2014; 10:1-11
  4. US Food and Drug Administration. Information for consumers (biosimilars). Available at FDA.gov. Accessed August 5, 2015. p3, PP 3-4.